S D Mikolajczyk

Summary

Affiliation: Beckman Coulter
Country: USA

Publications

  1. ncbi request reprint Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease
    Stephen D Mikolajczyk
    Beckman Coulter, Inc, San Diego, CA, USA
    Rinsho Byori 52:223-30. 2004
  2. ncbi request reprint Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer
    Yoshio Naya
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Urol Oncol 23:16-21. 2005
  3. ncbi request reprint Ala217 is important for the catalytic function and autoactivation of prostate-specific human kallikrein 2
    S D Mikolajczyk
    Hybritech Incorporated, San Diego, California 92196 9006, USA
    Eur J Biochem 246:440-6. 1997
  4. ncbi request reprint Are multiple markers the future of prostate cancer diagnostics?
    Stephen D Mikolajczyk
    Beckman Coulter, Inc, San Diego, CA 92121, USA
    Clin Biochem 37:519-28. 2004
  5. ncbi request reprint A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer
    S D Mikolajczyk
    Hybritech, Inc, San Diego, California 92121, USA
    Cancer Res 61:6958-63. 2001
  6. ncbi request reprint Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer
    Stephen D Mikolajczyk
    Beckman Coulter, Inc, San Diego, CA, USA
    Clin Chem 50:1017-25. 2004
  7. ncbi request reprint Seminal plasma contains "BPSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia
    S D Mikolajczyk
    Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc, San Diego, California 92196 9006, USA
    Prostate 45:271-6. 2000
  8. ncbi request reprint A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue
    S D Mikolajczyk
    Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc, San Diego, CA 92121, USA
    Cancer Res 60:756-9. 2000
  9. ncbi request reprint Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue
    S D Mikolajczyk
    Hybritech Inc, San Diego, California 92121, USA
    Cancer Res 59:3927-30. 1999
  10. ncbi request reprint Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1
    S D Mikolajczyk
    Hybritech Incorporated, a subsidiary of Beckman Coulter Inc, San Diego, CA 92196 9006, USA
    Int J Cancer 81:438-42. 1999

Collaborators

Detail Information

Publications32

  1. ncbi request reprint Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease
    Stephen D Mikolajczyk
    Beckman Coulter, Inc, San Diego, CA, USA
    Rinsho Byori 52:223-30. 2004
    ..The BPH-associated BPSA and cancer-associated proPSA forms are complementary and provide improved detection of prostate cancer from benign disease...
  2. ncbi request reprint Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer
    Yoshio Naya
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Urol Oncol 23:16-21. 2005
    ..Disease-associated isoforms of the prostate-specific antigen (PSA) have recently been identified. We evaluated the efficacy of using precursor isoforms of PSA (pPSA) and their ratios for the detection of prostate cancer...
  3. ncbi request reprint Ala217 is important for the catalytic function and autoactivation of prostate-specific human kallikrein 2
    S D Mikolajczyk
    Hybritech Incorporated, San Diego, California 92196 9006, USA
    Eur J Biochem 246:440-6. 1997
    ..These results indicate that Ala217 is a key residue affecting the catalytic properties of hK2...
  4. ncbi request reprint Are multiple markers the future of prostate cancer diagnostics?
    Stephen D Mikolajczyk
    Beckman Coulter, Inc, San Diego, CA 92121, USA
    Clin Biochem 37:519-28. 2004
    ....
  5. ncbi request reprint A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer
    S D Mikolajczyk
    Hybritech, Inc, San Diego, California 92121, USA
    Cancer Res 61:6958-63. 2001
    ..Thus, [-2]pPSA, once formed, is a stable but inactive isoform of PSA. Truncated [-2]pPSA may represent an important new diagnostic marker for the early detection of PCa...
  6. ncbi request reprint Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer
    Stephen D Mikolajczyk
    Beckman Coulter, Inc, San Diego, CA, USA
    Clin Chem 50:1017-25. 2004
    ..Immunoassays were developed to measure specific proPSA forms containing propeptides of 2, 4, and 7 amino acids [(-2)proPSA, (-4)proPSA, and (-7)proPSA, respectively]...
  7. ncbi request reprint Seminal plasma contains "BPSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia
    S D Mikolajczyk
    Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc, San Diego, California 92196 9006, USA
    Prostate 45:271-6. 2000
    ..BPSA was purified and found to contain a characteristic clip between Lys182 and Ser183. We now describe the identification of BPSA in seminal plasma...
  8. ncbi request reprint A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue
    S D Mikolajczyk
    Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc, San Diego, CA 92121, USA
    Cancer Res 60:756-9. 2000
    ..These results demonstrate that pPSA is more highly correlated with prostate cancer than with BPH. The pPSA in serum may represent a more cancer-specific form of PSA that could help distinguish prostate cancer from BPH...
  9. ncbi request reprint Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue
    S D Mikolajczyk
    Hybritech Inc, San Diego, California 92121, USA
    Cancer Res 59:3927-30. 1999
    ..The physiological role of PI-6 in the prostate and its relationship to hK2 and prostate cancer are under investigation...
  10. ncbi request reprint Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1
    S D Mikolajczyk
    Hybritech Incorporated, a subsidiary of Beckman Coulter Inc, San Diego, CA 92196 9006, USA
    Int J Cancer 81:438-42. 1999
    ..Our current results suggest that the increased hK2 expression in prostate cancer tissues could influence cancer biology not only by activation of uPA but also by inactivation of its primary inhibitor, PAI-1...
  11. ncbi request reprint The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia
    M S Saedi
    Hybritech Incorporated, Beckman Coulter, Inc, San Diego, CA 92126, USA
    Clin Chem 44:2115-9. 1998
    ..In addition, prohK2 in human sera is associated with prostate disease and thus may be a useful marker for prostatic cancer and BPH...
  12. ncbi request reprint Human kallikrein 2 (hK2), but not prostate-specific antigen (PSA), rapidly complexes with protease inhibitor 6 (PI-6) released from prostate carcinoma cells
    M S Saedi
    Hybritech Inc, San Diego, CA, USA
    Int J Cancer 94:558-63. 2001
    ..The differential staining pattern of PI6 in tissues suggests a complex regulation of PI-6 expression that may play a role in other aspects of neoplastic progression...
  13. ncbi request reprint Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors
    S D Mikolajczyk
    Hybritech Incorporated, San Diego, CA 92196 9006, USA
    Prostate 34:44-50. 1998
    ..It is a serine protease expressed in human prostate epithelial cells which has 78% sequence identity with prostate-specific antigen (PSA). PSA is a widely used biochemical marker for prostate cancer...
  14. ncbi request reprint Benign prostatic hyperplasia-associated prostate-specific antigen (BPSA) shows unique immunoreactivity with anti-PSA monoclonal antibodies
    T J Wang
    Hybritech Incorporated, San Diego, USA Scott Department of Urology, Baylor College of Medicine and The Methodist Hospital, Houston, USA
    Eur J Biochem 267:4040-5. 2000
    ..Measurement of BPSA levels in the serum may help discriminate benign prostatic hyperplasia from early prostate cancer...
  15. ncbi request reprint Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate
    H G Rittenhouse
    Research and Development Department, Hybritech Incorporated, Beckman Coulter, Inc, San Diego, California, USA
    Crit Rev Clin Lab Sci 35:275-368. 1998
    ..The production of hK2 protein in active protease form and specific monoclonal antibodies to the hK2 antigen will allow extensive future studies delineating the physiological and clinical utility of this new prostate antigen...
  16. ncbi request reprint Development of a dual monoclonal antibody immunoassay for total human kallikrein 2
    J A Finlay
    Research Department, Hybritech Inc, a subsidiary of Beckman Coulter, Inc, San Diego, CA 92121, USA
    Clin Chem 47:1218-24. 2001
    ....
  17. ncbi request reprint Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer
    Anil V Parwani
    Division of Pathology Informatics and Genito Urinary Pathology, Univeristy of Pittsburgh Medical Center Shadyside Hospital, Department of Pathology, Pittsburgh, PA 15232, USA
    Am J Surg Pathol 30:1231-6. 2006
    ..A panel of markers, including proPSA, should be performed when metastatic prostate carcinoma is in the differential diagnosis...
  18. ncbi request reprint Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer
    Eduardo I Canto
    Baylor Prostate Center, Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA
    Urology 63:905-10; discussion 910-1. 2004
    ....
  19. ncbi request reprint Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen
    William J Catalona
    Washington University, St Louis, Missouri, USA
    J Urol 171:2239-44. 2004
    ..Pro forms of prostate specific antigen (PSA) have been reported to be more cancer specific markers of prostate cancer than total PSA and they also may preferentially detect the more aggressive forms of the disease...
  20. ncbi request reprint Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer
    Yoshio Naya
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Urology 63:492-8. 2004
    ..We evaluated the efficacy of precursor isoforms of PSA (pPSA) and an internally cleaved form of PSA referred to as the benign prostatic hyperplasia-associated PSA (BPSA) for the detection of prostate cancer...
  21. ncbi request reprint Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml
    William J Catalona
    Washington University, St Louis, Missouri, USA
    J Urol 170:2181-5. 2003
    ..Serum pPSA was measured in the clinically relevant early detection PSA range of 2 to 10 ng/ml...
  22. ncbi request reprint Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml
    Masood A Khan
    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA
    J Urol 170:723-6. 2003
    ..There is increasing evidence that proPSA is associated preferentially with prostate cancer. The objective of this study was to determine whether proPSA can influence the detection of early prostate cancer...
  23. ncbi request reprint Alterations in nuclear structure and expression of proPSA predict differences between native Japanese and Japanese-American prostate cancer
    Robert W Veltri
    Department of Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Urology 68:898-904. 2006
    ..To differentiate the benign and/or malignant epithelial cells in prostate cancer (PCa) glands of native Japanese (NJ) and Japanese-American (JA) men using biomarkers...
  24. ncbi request reprint Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen
    Theresa Y Chan
    Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland 21231, USA
    Urology 62:177-81. 2003
    ..Pro-PSA have previously been shown to be more concentrated in prostate cancer tissue extracts than in benign tissue...
  25. ncbi request reprint Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis
    Lori J Sokoll
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    Urology 61:274-6. 2003
    ..5 to 4.0 ng/mL total PSA range. pPSA, the precursor form of PSA that contains a 7 amino acid leader peptide, and truncated forms such as [-2]pPSA and [-4]pPSA can be measured in serum by research immunoassay...
  26. ncbi request reprint Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease
    Harry J Linton
    Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc, 7330 Carroll Road, San Diego, CA 92121, USA
    Clin Chem 49:253-9. 2003
    ..We developed an immunoassay to determine the concentration of BPSA in the serum of men with BPH...
  27. ncbi request reprint Free prostate-specific antigen in serum is becoming more complex
    Stephen D Mikolajczyk
    Hybritech Incorporated, San Diego, California 92121, USA
    Urology 59:797-802. 2002
  28. ncbi request reprint Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression
    Iacovos P Michael
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada
    J Biol Chem 281:12743-50. 2006
    ..Our results uncover a kallikrein proteolytic cascade pathway in the prostate that participates in seminal clot liquefaction and probably in prostate cancer progression...
  29. ncbi request reprint Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis/chronic pelvic pain syndrome
    Robert B Nadler
    Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Urology 67:337-42. 2006
    ....
  30. ncbi request reprint Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%
    Masood A Khan
    Department of Urology, James Buchanan Brady Urological Institute and the Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, Maryland 21287 2101, USA
    Urology 64:1160-4. 2004
    ..A low percent free PSA value indicates a greater risk of cancer, but only 30% to 50% of men with percent free PSA levels of less than 15% actually have cancer at biopsy...
  31. ncbi request reprint Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer
    Stephen D Mikolajczyk
    Beckman Coulter, Inc, San Diego, CA 92121 2302, USA
    Keio J Med 52:86-91. 2003
    ..001). ProPSA was superior to %FPSA and complexed PSA in the 4-10 ng/ml PSA range (AUC = 0.689, 0.637 and 0.538, respectively). ProPSA represents a more cancer-specific form of PSA that better discriminates prostate cancer from BPH...
  32. doi request reprint Prostate specific antigen assay standardization bias could affect clinical decision making
    Stacy Loeb
    Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 180:1959-62; discussion 1962-3. 2008
    ..Most commercial prostate specific antigen assays are standardized to the WHO 90:10 standard or aligned with the original Hybritech assay with potentially disparate results...